脑龄差与多发性硬化患者躯体残疾及认知障碍的关联
本研究在1966年出生的同年龄多发性硬化患者与健康对照中,用机器学习从T1加权MRI计算脑预测年龄差(brain-PAD),发现患者脑龄差较对照高9.7年,且与病程、EDSS、9HPT、T25FWT及认知损害相关,并较脑实质分数(BPF)提供额外解释价值。
要点
- 同年龄队列中多发性硬化患者脑龄差较健康对照高9.7年。
- 脑龄差越高,EDSS、9HPT、T25FWT表现越差。
- 脑龄差在BPF之外对临床结局有额外解释价值。
核心结论
- 在同年龄无年龄混杂的队列中,更大的脑龄差与更差的残疾和认知测试表现相关,提示brain-PAD可作为多发性硬化神经退行和疾病严重度的标志物。
研究设计与样本
- 横断面队列研究,在荷兰纳入1966年出生的116名健康对照和237名多发性硬化患者。
- 脑龄差由3D T1加权脑MRI经机器学习(brainageR软件)预测脑龄减去实际年龄计算。
- 残疾用EDSS、9HPT和T25FWT评估,认知用多发性硬化最小认知功能评估组合评估。
主要发现
- 多发性硬化患者脑龄差较健康对照高9.7年(SE=0.82,p<0.0001)。
- 病程越长脑龄差越高(β=0.21,p<0.001)。
- 脑龄差越高与T25FWT(β=0.0063,p<0.05)、9HPT(β=0.0074,p<0.001)和EDSS(β=0.028,p<0.05)表现越差相关。
- 认知损害的多发性硬化患者脑龄差高于认知保留患者和健康对照(p<0.0001)。
- 脑龄差在临床结局指标上较BPF有额外解释价值。
临床怎么用
- 可将brain-PAD作为多发性硬化神经退行和疾病严重度的辅助影像标志物。
- 脑龄差升高提示需关注躯体残疾和认知损害风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The brain-predicted age difference (brain-PAD) is a novel marker of neurodegeneration in multiple sclerosis (MS). Brain-PAD has been associated with clinical disability in heterogeneous MS patient cohorts of varying ages and disease durations. In this study, we investigate the relation between clinical disability and brain-PAD in a unique birth-year cohort of people with MS (pwMS) and healthy controls (HCs) of the same age all born in 1966, eliminating age as a confounding factor. METHODS: This was a cross-sectional cohort study conducted in the Netherlands. Disability was quantified using the expanded disability status scale (EDSS), 9-hole peg test (9HPT), and the timed 25-foot walk test (T25FWT). Cognition was assessed using the Minimal Assessment of Cognitive Function in MS battery. The brain-PAD was calculated by subtracting the person's chronological age from the predicted brain age derived from 3-dimensional T1-weighted brain MRI scans using machine learning (brainageR software). Brain-PAD for HCs and MS subtypes (relapsing remitting, secondary progressive, and primary progressive) were compared using a generalized linear model. The relation between brain-PAD and disease duration and disability and cognitive measures were tested using univariate linear regression. In addition, the clinical explanatory value added by brain-PAD to those of brain parenchymal fraction (BPF) and T2 lesion volume was investigated. RESULTS: The study included 116 HC (mean age 52.9 ± 1.1 years, 61% female) and 237 pwMS (mean age 52.9 ± 0.9 years, median disease duration 16.3 years [interquartile range 8.2-24.4] and a median EDSS of 3.5 [interquartile range 2.5-4.0]). Brain-PAD was higher in pwMS compared with HC by 9.7 years (SE = 0.82, p < 0.0001). Longer disease duration was associated with a higher brain-PAD (β = 0.21, p < 0.001). A higher brain-PAD was associated with worse performance on the T25FWT (β = 0.0063, p < 0.05), 9HPT (β = 0.0074, p < 0.001), and EDSS (β = 0.028, p < 0.05). Brain-PAD was higher for cognitively impaired people with MS, compared with cognitively preserved pwMS and HC (p < 0.0001). Brain-PAD had added explanatory value over BPF in clinical outcome measures. DISCUSSION: In a cohort unbiased by age differences, greater brain ageing was associated with worse performance on disability and cognitive tests, underscoring the potential of brain-PAD as a marker for neurodegeneration and disease severity in MS.
引用
- Bos L, Wink AM, Cole JH, et al. Association of Brain Age With Physical Disability and Cognitive Impairment in People With Multiple Sclerosis of the Same Age. Neurology. 2025. PMID: 41411602. doi:10.1212/WNL.0000000000214527
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。